Gilead Defends Growth Prospects As Veklury Sales Drive Q3 Revenue Surge

Guidance Lowered For Sales Excluding The COVID-19 Drug

Third quarter revenue rose 13% year-over year to $7.4bn but fell 3% without Veklury to $5.4bn as the HCV and HIV franchises felt continued pandemic and generics impacts.

Gilead sign at their headquarters in Foster City
Gilead expects up to $26.3bn in 2021 product sales, $21.5bn excluding Veklury • Source: Alamy

Gilead Sciences, Inc. reported a 13% increase in third quarter revenue to $7.4bn on 28 October but the growth was driven almost entirely by Veklury (remdesivir) for which sales more than doubled from $829m in Q2 to $1.9bn in Q3 as COVID-19 hospitalizations surged due to the Delta variant of the novel coronavirus. Without Veklury, however, sales fell 3% to $5.4bn despite a 20% spike in sales to $2.3bn for Gilead’s newest HIV blockbuster Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide).

Gilead executives noted during a same-day earnings conference call that they remain confident in the company’s growth prospects despite ongoing...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.